DexCom, Inc. vs InMode Ltd — how do they compare? DexCom, Inc. trades at $90.54 (market cap $33.79B), while InMode Ltd trades at $15.26 (market cap $872.08M). The key difference: DexCom, Inc. is far larger — about 38.7× InMode Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | INMD | |
|---|---|---|
Market Cap | $33.79B | $872.08M |
Sector | Health | Technology |
52-Week High | $89.53 | $16.62 |
52-Week Low | $54.84 | $12.76 |
Enterprise Value | $33.24B | $375.42M |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
INMD trades at $15.24, up 0.33% on the day, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company maintains strong profitability with a 20.69% net income margin and attractive valuation ratios, including a P/E of 12.52. Recent news highlights include Q2 2026 results consistent with the prior year and an unsolicited acquisition proposal from Steel Partners at $16.75 per share.
The stock presents a value opportunity given its low valuation multiples and high margins, but faces near-term uncertainty from shareholder activism, a securities fraud investigation, and potential acquisition volatility. Analyst sentiment is divided between Buy and Hold ratings, reflecting the balance between fundamental strength and corporate governance concerns.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →